The DOI matches its Crossref record; 97 of the 98 references it cites were found in a registry or an index.
TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice
Open accessAbstract
TGFbeta1 has been implicated in cell cycle control and carcinogenesis. To address the exact function of TGFbeta1 in skin carcinogenesis in vivo, mice with TGFbeta1 expression targeted to keratinocytes were subjected to long-term chemical carcinogenesis treatment. TGFbeta1 showed biphasic action during multistage skin carcinogenesis, acting early as a tumor suppressor but later enhancing the malignant phenotype. The transgenics were more resistant to induction of benign skin tumors than controls, but the malignant conversion rate was vastly increased. There was also a higher incidence of spindle cell carcinomas, which expressed high levels of endogenous TGFbeta3, suggesting that TGFbeta1 elicits an epithelial-mesenchymal transition in vivo and that TGFbeta3 might be involved in maintenance of the spindle cell phenotype. The action of TGFbeta1 in enhancing malignant progression may mimic its proposed function in modulating epithelial cell plasticity during embryonic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, TGF-β3 is clearly expressed by stromal CAFs and mesenchymal tumor cells41,70,247”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [41]
Citations
Cites
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U., Liotta, L. A., Falanga, V., & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,867
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S. D., Wang, J., Myeroff, L. L., Parsons, R. E., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,267
Kaartinen, V., Voncken, J. W., Shuler, C. F., Warburton, D., Bu, D., Heisterkamp, N., & Groffen, J. (1995) · Nature Genetics · doi:10.1038/ng1295-415 · Cited by 1,042
Miettinen, P. J., Ebner, R., Lopez, A. R., & Derynck, R. (1994) · The Journal of Cell Biology · doi:10.1083/jcb.127.6.2021 · Cited by 939
Transforming growth factor–β3 is required for secondary palate fusion
Proetzel, G., Pawlowski, S. A., Wiles, M. V., Yin, M., Boivin, G. P., Howles, P. N., Ding, J., Ferguson, M. W. J., & Doetschman, T. (1995) · Nature Genetics · doi:10.1038/ng1295-409 · Cited by 908
Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., & Berger, W. H. (1987) · PubMed · Cited by 898
Kimelman, D., & Kirschner, M. W. (1987) · Cell · doi:10.1016/0092-8674(87)90110-3 · Cited by 872
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Springer eBooks · doi:10.1007/978-1-4612-3210-0_8 · Cited by 869
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1990) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-49295-2_8 · Cited by 744
Ansari, B., Coates, P. J., Greenstein, B., & Hall, P. A. (1993) · The Journal of Pathology · doi:10.1002/path.1711700102 · Cited by 578
Research works printed but not linked: 11
- Arteaga, 1990, Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies, Cell Growth Differ., 1, 367
- Caulin, 1995, Chronic exposure of cultured transfected mouse epidermal cells to TGFβ1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype, Cell Growth Differ., 6, 1027
- Cui, W., and Akhurst, R.J. (1996). Transforming growth factors β: biochemistry and biology in vitro and in vivo. In Growth Factors and Cytokines in Health and Disease, C. Bondy and D. LeRoith, eds. (Greenwich, Connecticut: JAI Press), in press.
- Cui, 1994, Lack of TGFβ1 expression in benign skin tumours of p53 null mice is prognostic for a high risk of malignant conversion, Cancer Res., 54, 5831
- Dlugosz, 1995, Autocrine transforming growth factor α is dispensible for v-ras-Ha-induced epidermal neoplasia, Cancer Res., 55, 1883
- Fowlis, 1992, Discordant TGFβ1 RNA and protein localisations during chemical carcinogenesis of the skin, Cell Growth Differ., 3, 81
- Fowlis, 1996, Altered epidermal growth control in vivo in transgenic mice expressing TGFβ1 from an inducible keratin gene promoter, Cell Growth Differ., 7, 679
- Gomella, 1989, Expression of transforming growth factor α in normal adult kidney and enhanced expression of transforming growth factors α and β in renal cell carcinoma, Cancer Res., 49, 6972
- Manning, 1991, Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF-β), Oncogene, 6, 1471
- Steiner, 1992, Transforming growth factor-β-1 overproduction in prostate cancer, Mol. Endocrinol., 6, 15
- Tennenbaum, 1992, Extracellular matrix receptors and mouse skin carcinogenesis, Cancer Res., 52, 2966
Cited by
Sorted by citations
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
TGF-β signalling from cell membrane to nucleus through SMAD proteins
Heldin, C., Miyazono, K., & ten Dijke, P. (1997) · Nature · doi:10.1038/37284 · Cited by 3,697
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,453
Metadata
- Authors
- Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., & Akhurst, R. J.
- Affiliations
- University of Glasgow (GB)
- Corresponding author
- Akhurst, Rosemary J
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1996-08
- Volume
- 86
- Issue
- 4
- Pages
- 531-542
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2026460094
- Cited by
- 628
- References
- 98
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 10 · 2023: 20 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 13 · 2017: 12 · 2016: 9 · 2015: 15 · 2014: 22 · 2013: 22 · 2012: 26
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Keywords
- TGF-β1, skin carcinogenesis, sarcomatoid carcinoma, keratinocytes, tumor suppressor, malignant progression, TGF-beta3, epithelial-mesenchymal transition, chemical carcinogenesis, transgenic mice, epithelial cell plasticity
- MeSH terms
- Animals, Carcinoma, Carcinoma, Squamous Cell, Cells, Cultured, Female, Immunologic Techniques, Keratins, Mice, Transgenic, Papilloma, Skin Neoplasms, Integrins, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
